REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it hired ...
In an area in northern China, cancer in the cardia, which is located between the esophagus and the stomach, occurs at high rates, and the cancer type has distinct features compared to Western ...
Future Cardia, a medical device company, announced an expanded collaboration with remote cardiac monitoring company, Artella Solutions. Future Cardia is developing an implantable cardiac monitoring ...
REHOVOT, ISRAEL / ACCESSWIRE / August 22, 2022 / Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today a successful ...
Partnership leverages ARTELLA’S Active State Monitoring SaaS platform and Certified Independent Diagnostic Testing Facility (IDTF) with Future Cardia’s Implantable Cardiac Devices. The companies began ...
Frequency of peritoneal metastasis (PM) as exclusion criteria in clinical trials of gastrointestinal (GI) cancers. Age-adjusted mortality rates (AAMRs) per 100,000 for trends related to gastric cancer ...
REHOVOT, Israel - Pi-Cardia Ltd. announced today that it successfully completed the First-in-Human (FIH) studies with its Leaflex™ Performer catheter. The Leaflex™ Performer is a trans-femoral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results